Stories from people navigating gastric cancer — diagnosis, treatment, caregiving, and the ordinary days in between.
3 stories
Oncology
ASTRUM-006 found an event-free survival benefit from adding serplulimab to perioperative SOX in PD-L1-positive, resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · September 28, 2026 · 7 min
Oncology
MATTERHORN found better event-free survival and pathologic response with perioperative durvalumab plus FLOT for resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Oncology
The FDA authorized two zanidatamab-based first-line strategies for unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Rayan Salih · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.